Select Page ::

Migrating species tend to ‘live fast and die young’ – UPI News

Posted on November 21, 2020 by Prof Baldwin

Nov. 17 (UPI) -- Want to live a long and healthy life? Experts in human longevity often stress the importance of staying active.

But new research suggests more sedentary animals -- species that stay put, avoiding long distance travel -- enjoy comparatively longer lifespans.

The findings, published Tuesday in the journal Nature Communications, suggest animal species that migrate tend to "live fast and die young."

For the study, scientists at the University of Exeter analyzed the development patterns and lifespans of some 1,300 mammal and bird species. They found species that migrate develop faster, reproduce earlier and generally live shorter lives than their more stationary peers.

Their analysis may explain why many migratory species are on the decline.

"Many species migrate over long distances and this requires substantial amounts of energy," lead study author Andrea Soriano-Redondo said in a news release.

"This energy cannot be used for other purposes such as self-maintenance or reproduction, so we would expect animals to adjust the amount of energy they use for these things," said Soriano-Redondo, a conservation biologist and research fellow at Exeter.

Instead of investing their energy in survival, migrating species focus on reproducing earlier and faster. The ability to generate offspring more rapidly may help migrating species offset the risks posed by their fast-paced lifestyle.

Researchers gauged the "pace-of-life" of hundreds of bird and mammal species by considering their longevity, age of female sexual maturity and the number of times a species can reproduce each year.

Several studies have highlighted the dangers climate change poses to migrating species. The latest research suggests changes in temperature and seasonal patterns can amplify the risks of what was already a perilous lifestyle.

"We have long thought that migration is a risky behavior," said study co-author Stuart Bearhop.

"Animals often take a chance when they migrate, hoping to find the right conditions in their destination. In the case of birds that migrate to the High Arctic, they arrive in spring and have a short window in which to breed," said Bearhop, professor of biology at Exeter's Center for Ecology and Conservation.

Read the rest here:
Migrating species tend to 'live fast and die young' - UPI News

Global Precision Medicine Software Market Professional Survey 2020 by Manufacturers, Share, Growth, Trends, Types and Applications, Forecast to 2026 -…

Posted on December 28, 2020 by Prof Baldwin

Global Precision Medicine Software Market 2020- This Research report will cover the impact of COVID-19 on this industry.

Global marketers Business Study provides the Precision Medicine Software industry market analysis with product scope, market revenue, forecast, growth rate, sales volume, and value. The study also describes the global players in the market and segmented by regions, type, and applications with forecast until 2026.

The Precision Medicine Software Market Research report sheds light on past research and provides accurate forecasts for the future, including other factors that influence growth rates. This comprehensive report provides a comprehensive analysis of influencing factors such as market dynamics (demand, supply, price, quantity, and other specific conditions), SWOT, PEST, and PORTER analysis which support the growth of the Precision Medicine Software industry.

Request A Free Sample Report Here: https://www.globalmarketers.biz/report/others/global-precision-medicine-software-market-report-2019,-competitive-landscape,-trends-and-opportunities/136862#request_sample

The analysis covers all aspects of the global analysis of the Precision Medicine Software market structure and reveals how the different market segments are growing in terms of consumption, production, sales, volume, and other important aspects. Analysts have also segmented the global market by products, applications, and Precision Medicine Software regions.

Leading Players List:

SOPHiA GENETICS SA (Switzerland)N-of-One, Inc. (US)Gene42, Inc. (Canada)LifeOmic Health, LLC (US)Translational Software, Inc. (US)IBM Watson Group (US)2bPrecise LLC (Israel)Roper Technologies(US)Koninklijke Philips N.V. (Netherlands)Qiagen(Germany)Foundation Medicine, Inc. (US)Pfizer, Inc., Merck & Co., Inc.(US)NantHealth, Inc. (US)Allscripts(US)Sunquest Information Systems Inc. (US)Human Longevity, Inc. (US)Abbott Laboratories(US)Tempus Labs, Inc. (US)GlaxoSmithKline plc(UK)Sanofi S.A.(France)Fabric Genomics (US)Syapse, Inc. (US)PierianDx, Inc. (US)Flatiron Health, Inc. (US)AstraZeneca plc(US)

Global Precision Medicine Software Market segments:

Global Precision Medicine Software Market By Type:

Cloud-basedOn-premise

Global Precision Medicine Software Market By Application:

Healthcare providersResearch centers & Government institutesPharmaceutical & Biotechnology companiesOther end users

Year End Sale!!! 40% Off On Selected Report. Ask For Discount :https://www.globalmarketers.biz/discount_inquiry/discount/136862

The key questions answered in the report are:

Inquiry Before Purchasehttps://www.globalmarketers.biz/report/others/global-precision-medicine-software-market-report-2019,-competitive-landscape,-trends-and-opportunities/136862#inquiry_before_buying

Key Points Of TOC:

Review the Complete TOC: https://www.globalmarketers.biz/report/others/global-precision-medicine-software-market-report-2019,-competitive-landscape,-trends-and-opportunities/136862#table_of_contents

See the rest here:
Global Precision Medicine Software Market Professional Survey 2020 by Manufacturers, Share, Growth, Trends, Types and Applications, Forecast to 2026 -...

Korea plans up to W10tr investment for biohealth by 2023 – The Korea Herald

Posted on November 21, 2020 by Prof Baldwin

President Moon Jae-in expresses appreciation for Samsung Biologics` 1.7 trillion won and Celltrion`s 500 billion won investments in biologics industry, promises 1.7 trillion won national budget for biohealth industry in 2021, at a memorandum of understanding ceremony held at Yonsei University Global Campus in Songdo, Incehon, on Wednesday. (Yonhap)

Samsung Biologics will pour 1.7 trillion won ($1.54 billion) into its new Plant 4, and Celltrion 500 billion won to its Global Life Science Research Lab and Plant 3. The Government also pledged 1.7 trillion won budget in 2021 for bio health industry, which is a 30 percent increased budget compared to last years, reflecting the growing interest from the Korean government to build up the national ecosystem for biologics industry. By 2023, the total amount of private investments for biohealth industry will amount to 10 trillion won, the Korean government projected.

President Moon Jae-in personally attended the memorandum of understanding ceremony Wednesday at Yonsei University Global Campus in Songdo to encourage and promise governmental support in the private companies endeavors.

Also among the attendees were Finance Minister Hong Nam-ki, who doubles as deputy prime minister for economic affairs, Industry Minister Sung Yoon-mo, Science Minister Choi Ki-young, Health Minister Park Neung-hoo and Drugs Minister Kim Gang-lib, as well as Incheon Mayor Park Nam-choon. Heads of parts and equipment companies Junghyun Plant and Wiatek and students in biologics and relevant fields were also included.

Koreas action plan for a more robust bio industry ecosystem is to inject 1.7 trillion won from the budget in 2021, up 30 percent from that assigned a year prior, and to foster specialized future experts and collaboration with small and medium-sized companies.

In the world market, the biologics industry is notching an annual average growth rate of 4 percent, higher than makers of ships at 2.9 percent and automakers at 1.5 percent, according to the government agencies.

Taking this into consideration, the biohealth players in Korea are seeking to create synergy by building an ecosystem for biologics in Songdo.

There are now over 60 bio-related companies in Songdo, including both Korean and global firms. These firms employ some 7,000 workers.

By 2023, about 10 trillion won of investment is expected to be made in the city by some 40 health care and venture capital firms, resulting in an annual 20 percent growth of manufacturing capacity and the additional employment of approximately 9,300.

The government envisions growing a workforce of some 47,000 in biologics by 2025 in a joint effort with the industry and academia. To that end, at Yonsei University Global Campus a center to foster biologics processing experts will be established.

In the big picture of nationwide efforts to grow the biologics industry, regional bio clusters of Songdo in Incheon, Wonju in Gangwon Province, Osong in North Chungcheong Province and Daegu will increase collaboration.

The governmental budget of 1.7 trillion won will prioritize pharmaceuticals, medical devices and digital health care, in that order.

Samsung Biologics groundbreaking ceremony for Plant 4 takes place Wednesday in Songdo, Incheon. (Samsung Biologics)

Projected to begin partial manufacturing from 2022 and full operations in 2023, Plant 4 will have capacity of 256,000 liters. This surpasses the record of Samsung Biologics Plant 3 as the largest biologics manufacturing plant in the world with 180,000 liters.

The Super Plant alone will sprawl across 238,000 square meters, nearing the combined land size of Samsung Biologics Plants 1, 2 and 3 combined, at 240,000 square meters.

The company will inject 1.74 trillion won to build the massive plant, and employ an additional workforce of 1,850.

Once Plant 4 is complete, Samsung Biologics will purchase another slab of land in Songdo to start a second campus of its facilities, Samsung Biologics CEO Kim Tae-han said at the ceremony.

Celltrions proposed Global Life Science Research Center (Celltrion)

The antibody maker is not stopping there -- Celltrion Chairman Seo Jung-jin said at Wednesdays event that the company is mulling Plant 4 in the near future, with aims to expand its total production output to 600,000 liters as fast as the company can manage.

If executed, this plan would triple Celltrions current manufacturing capacity of 190,000 liters in a single generation. According to Seo, Celltrion is mulling facilities of 200,000 liters in Songdo, with the rest located overseas.

Global Life Science Research Center will complete construction by July 2022 and accommodate 2,500 additional researchers. Plant 3 will have its groundbreaking in 2021 and finish building by May 2023.

How we compete against multinational companies with more than a century of history is through advanced technology and our fighter spirit, Seo said.

Celltrion will carry out in stages investments of 40 trillion won through 2030.

Celltrion began in 2002 as a six-person startup. This year, it is on track to place No. 30-35 among some 300,000 biologics companies in terms of operating profit.

With Samsung Biologics and Celltrions investments, Korea as a nation will have the capacity to manufacture 910,000 liters of biologics a year. Songdo as a city will have the worlds biggest manufacturing output of biologics substances.

The reason we must combine forces in the bio industry is clear, because it is something we can be good at, said President Moon Jae-in at the ceremony.

The answer to humanitys wishes to live long healthily lies in the bio industry, Moon said. And so long as human longevity continues to lengthen, the bio industry will always be a future growth driver.

Just a few years ago, biologics was an area with a great hurdle. When the free trade agreement between the US and Korea was signed, we expected bio to suffer among the worst blows, Moon said.

But now the Republic of Korea is rewriting history for the bio industry. For now, we only account for 2 percent of the world bio market. But armed with global No. 2 capability to manufacture biopharmaceuticals, we now have the growing confidence that we can achieve greater goals, Moon said.

Heading forward, Koreas Industry, Science and Health ministries would work to combine electronics, chemicals, energy, manufacturing, data, networks, artificial intelligence and semiconductors with biotechnologies.

This is anticipated to bring forth innovative research on human-augmented robots, cerebral computer interfaces, eco-friendly plastics, functional fibers, renewable green energy and breakthroughs in manufacturing models leveraging microorganisms.

Big data with biotech will enable customized personal treatments, while communications will enable real-time patient monitoring. Artificial intelligence will help conduct research more quickly, with semiconductors and software technologies aiding in early diagnoses.

By Lim Jeong-yeo (kaylalim@heraldcorp.com)

Longevity and Anti-senescence Therapy Market: Opportunities, Demand and Forecasts, size COVID-19 2023 – ICOTodayMagazine

Posted on November 21, 2020 by Prof Baldwin

The global longevity and anti-senescence therapies market should grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11698

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Summary

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography. Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

Request for Report Discount:https://www.trendsmarketresearch.com/report/discount/11698

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

More Info of Impact [emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/11698

Precision Medicine Software Market Is Expected To Witness Lucrative Growth Over The Forecast Period Till 2026 – re:Jerusalem

Posted on November 2, 2020 by Prof Baldwin

According to a new report published by Allied Market Research, titled, Precision Medicine Software Marketby Delivery Mode (On-premise and Cloud-based), Application (Oncology, Pharmacogenomics, Rare Diseases, and Others), and End User (Healthcare Providers, Research Centers & Government Institutes, and Pharmaceutical & Biotechnology Companies): Global Opportunity Analysis and Industry Forecast, 2019-2026

The global market size of Precision Medicine Software Market is $XX million in 2018 with XX CAGR, and it is expected to reach $XX million by the end of 2026 with a CAGR of XX% from 2019 to 2026.

Download Free Report Sample (320 Pages PDF with Insights) @https://www.alliedmarketresearch.com/request-sample/5675

Precision medicine is an emerging medical approach undertaken by medical practitioners for the treatment of a patient, followed with medical decisions, treatments, practices, or products being tailored to the individual patient. Appropriate or optimal therapies may be employed based on variability in the patients genetic profile, environment, and lifestyle for each person. The diagnostic testing can be based on the context of an individuals genetic profile or other molecular or cellular analysis.

The emergence of precision medicine has addressed the dire need for better diagnostic and analytical tools. Precision medicine software combines the clinical and molecular data to provide with valuable insights to determine the ideal therapeutic course of treatment. Moreover, it provides with a wide range of applications in both the diagnostics and clinical areas for better understanding of diseases such as cancer, searching for new biomarkers, researching new therapies, repurposing existing drugs, and stratifying patients for clinical trials.

The precision medicine software market is segmented on the basis of delivery mode, end user, application, and region.

Based on delivery mode, the precision medicine software market is classified into on-premise and cloud-based systems.

Depending on end-user, it is categorized into healthcare providers, research centers & government institutes, and pharmaceutical & biotechnology companies.

By application, it is segregated into oncology, pharmacogenomics, rare diseases, and others.

Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/5675

The Major Key Players Are:

Synapse, Inc., Allscripts Healthcare Solutions, Inc. (2bPrecise LLC), Roche Holdings, Inc. (Foundation Medicine, Inc.), Fabric Genomics, Inc., Sophia Genetics SA, PierianDx, Inc., Qiagen N.V. (N-of-One, Inc.), Human Longevity, Inc., Roper Technologies, Inc. (Sunquest Information Systems, Inc.), Gene42, Inc.

The other players in the value chain includes:

Translational Software, Inc., LifeOmic Health, LLC, NantHealth, Inc., Tempus Labs, Inc., Flatiron Health, Inc., IBM Watson Group, and Koninklijke Philips N.V.

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of Market Research Reports and Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesToll Free (USA/Canada):+1-800-792-5285, +1-503-894-6022, +1-503-446-1141UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1-855-550-5975help@alliedmarketresearch.comWeb:https://www.alliedmarketresearch.com

What’s Wrong With Health Care in the United States? – Psychiatric Times

Posted on November 7, 2020 by Prof Baldwin

Health care in the United States is in poor health, its quality steadily declining since the 1960s. According to the World Economic Forum , in the 1950s the United States ranked first among the developed nations in the quality of health care. But now, despite enlisting renowned physicians, public health experts, economists, business leaders, and specialists in the treatment of ailing systems, we rank near the bottom.

What is the explanation? Is something being overlooked in the current effort to improve medical care? Do we not understand the cause of this fatal condition? The authors believe it is the importance of relationships that is being ignored; the physician-patient relationship, family relationships, and relationship systems in the community. Four key elements in our current health care system are responsible for this failure to acknowledge these critical relationships.

Interchangeability of parts

The foundation of the Industrial Revolution was the ability to create interchangeable parts. For example, workers on an assembly line build excellent automobiles cost-effectively. Health care administrators are using that model in medicine. The model of industrialized medicine works poorly when dealing with human beings, and is cost-effective only in the short run. Patients and practitioners are not interchangeable parts. Patients and their illnesses are too complex for a one-size-fits-all design. A health care model that does not recognize each patient as a unique person existing in a unique network of relationshipswith medical practitioners, family, and communityresults in increasingly poor outcomes, as the data demonstrate.

Systematic ignoring of the physician-patient and physician-family relationships

Treatment outcomes decline when patients see a different physician at each visit. The industrialized model excludes the importance of relatedness between physician and patient, losing the stabilizing relational linkages. For example, patients in hospitals cared for by their primary care physician are more likely to be discharged home and less likely to die within 30 days than those cared for by hospitalists who do not have an ongoing relationship with the patient and family.

The lack of sustained relationships between physicians and patients, and physicians and families, in the context of their community, impairs the effectiveness of treatment. It is costly to the physicians sense that their work is meaningful, and thus costly to physician morale. Systems that fail to attend to the physician-patient relationship lead to decreased treatment effectiveness, physician burnout, early retirement, and increased rates of physician suicide.

Healing is more likely in the context of families than healing in isolation

Without attention to context, our words, actions, and experience have no meaning. Family and community relationships are the context of our patients lives. Strong social connections are associated with increased longevity. For example, marriage is a protective factor against cardiac disease and the death of a spouse is associated with increased rates of physical illness in the surviving spouse. For individuals with a chronic illness, treatment without consideration of family and community appears simpler and more efficient, but leads to sterile, out-of-context, uninformed treatment, blinding both the patient and the physician from seeing both the illness and the solution.

The undermining and erosion of family and community

Regulations and reimbursement systems that reduce the medical interaction to a specific procedure diminish the involvement of families and communities in a patients recovery. The Health Information Portability and Accountability Act (HIPAA), for example, which was established to protect patient confidentiality, immediately became an obstacle to communication with the people in the patients life who can help with follow-up appointments, medication adherence, continuity of care, and emotional support.

Treating the correct condition

The 4 elements described point to both the fatal condition and its solution. Attention to the whole person, focusing on relationships with physicians and nurses, patients and families, and the web of community relationships available in every community to every patient, helps people get and stay healthy. Any potential solution to the health care system that ignores relationships will always be ineffective. If industrial medicine worked, and at this point weve done that experiment, costs would not be rising, patients and physicians would not be dissatisfied, and health would be improving.

Dr Copansis Adjunct Associate Professor, Geisel School of Medicine at Dartmouth, Hanover, NH.Dr Rahmaniis training director of Child and Adolescent Psychiatry at the University of Florida.

*Members of the Research Committee, Group for the Advancement of Psychiatry also include Dr John Beahrs, Emeritus Professor of Psychiatry, Oregon Health and Science University, Portland; Dr Allan Josephson, (Former) Professor and Chief, Division of Child and Adolescent Psychiatry, University of Louisville School of Medicine; Dr David Keith, Professor Emeritus, Department of Psychiatry and Behavioral Sciences, Upstate Medical Center, Syracuse, NY; Dr Patrick Malone (19442016); Dr Alan Swann, Professor of Psychiatry, Baylor College of Medicine, and staff psychiatrist, Houston VA Medical Center; Dr William Swift, Emeritus Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health, Madison; Dr Johan Verhulst (19382019); and Dr Douglas Kramer, Emeritus Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health, Madison, and Chair, GAP Research Committee.

Continue reading here:
What's Wrong With Health Care in the United States? - Psychiatric Times

New Research Uncovers Why Bats Excel As Viral Reservoirs Without Getting Sick – SciTechDaily

Posted on October 28, 2020 by Prof Baldwin

Right wing of a cave nectar bat (Eonycteris spelaea) extended to show the forearm, plagiopatagium, and supplying vasculature. Credit: Zhu Feng, Duke-NUS Medical School

Study confirms bats adopt multiple strategies to reduce pro-inflammatory responses, thus mitigating potential immune-mediated tissue damage and disease. Findings provide important insights for medical research on human diseases.

Bats act as reservoirs of numerous zoonotic viruses, including SARS-CoV, MERS CoV, Ebola virus, andmost likelySARS-CoV-2, the pathogen behind the ongoing coronavirus pandemic. However, the molecular mechanisms bats deploy to tolerate pathogenic viruses has remained unclear.

Now scientists from Duke-NUS Medical School, Singapore, have discovered novel molecular mechanisms that allow bats to tolerate zoonotic viruses without getting sick. Published this week in the Proceedings of the National Academy of Sciences (PNAS), the study suggests that bats adopt unique strategies to prevent overactive immune responses, which protects them against diseases caused by zoonotic viruses.

The team examined three bat speciesPteropus alecto (black fruit bat), Eonycteris spelaea (cave nectar bat), and Myotis davidii (Davids myotis bat)and identified mechanisms that balance the activity of key proteins that play a major role in mediating immunity and inflammatory responses in mammals. These mechanisms enable bats to harbour and transmit zoonotic pathogens without setting off the detrimental consequences of immune activation.

One of the mechanisms bats use is to reduce the levels of caspase-1, a protein that triggers a key inflammatory cytokine protein, interleukin-1 beta (IL-1). Another mechanism they employ hampers the maturation of interleukin-1 beta cytokines through a finely-tuned balancing between caspase-1 and IL-1.

Suppression of overactive inflammatory responses improves longevity and prevents age-related decline in humans. Our findings may offer potential insights to the development of new therapeutic strategies that can control and treat human infectious diseases, said Professor Wang Linfa, senior and corresponding author of the study from Duke-NUS Emerging Infectious Diseases (EID) Programme.

This study exemplifies the world-class research led by our talented faculty to advance fundamental scientific knowledge. Professor Wangs research is all the more important in the context of COVID-19, by contributing to a greater understanding of how zoonotic diseases persist in nature, and potentially aiding new approaches to managing future outbreaks, said Professor Patrick Casey, Senior Vice-Dean for Research, Duke-NUS Medical School.

Reference: Complementary regulation of caspase-1 and IL-1 reveals additional mechanisms of dampened inflammation in bats by Geraldine Goh, Matae Ahn, Feng Zhu, Lim Beng Lee, Dahai Luo, Aaron T. Irving, and Lin-Fa Wang, 26 October 2020, Proceedings of the National Academy of Sciences.DOI: 10.1073/pnas.2003352117

ADM spotlights holistic health and beyond the bun plant-based developments in 2021 outlook – FoodIngredientsFirst

Posted on November 2, 2020 by Prof Baldwin

02 Nov 2020 --- Looking ahead into 2021, ADM is highlighting the staying power of accelerated themes in F&B product development, such as a spike in demand for brain-boosting formulas and ingredients for gut health. The agri-food supplier also calls attention to beyond the bun diversification of plant-based categories.

The company explores these market dynamics through its newly unveiled global trends for 2021.

Our experts pay close attention to whats happening in the global marketplace, including tracking large, transformative global macrotrends that are key to understanding long-term impacts on consumer culture and behavior, Ana Ferrell, vice president of marketing at ADM tellsFoodIngredientsFirst.

Through that work, weve pinpointed five key trends that we expect to transform food and beverage innovation for 2021 based on their accelerating adoption and opportunities for future advancement.

Click to EnlargeThe upcoming year is hailed as a year of innovation by ADM, marked by significant breakthroughs in nutrition.The themes are based on research from the ADMs proprietary OutsideVoice consumer insights platform. Each of these trends is strongly influenced by behavioral and societal changes that have emerged since the beginning of the COVID-19 pandemic.

Ferrell compares the lifespan of a product trend to a passing fad. A fad is generally considered an object or behavior that achieves short-lived popularity before fading away, while a trend evolves into a long-term or even permanent change.

We believe relevancy to the consumer drives longevity when a trend aligns with your personal values it has more staying power than something like the color of the year or the latest spicy food.

The upcoming year is hailed as a year of innovation by ADM, marked by significant breakthroughs in nutrition. The global health crisis has changed consumer preferences in new and unexpected ways, comments Vince Macciocchi, president of nutrition at ADM.

We are seeing a heightened demand for foods and beverages that support immune systems, enhance our mood and reduce our environmental impact, driven in part by emerging human tensions.

The five trends pegged by ADM include:

1. A more proactive approach to nourishing the body and mindADM research finds that 31 percent of consumers are purchasing more items tailored for their health, and 50 percent report a preference for foods and beverages that naturally contain beneficial ingredients.

There is sustained demand on the market for functional health benefits aimed at supporting immune systems, enhancing mood and sustaining energy.

Sensory elements like flavor and color are also playing an increasingly crucial role in this context. Last month, ADM turned the spotlight on signaling ingredients formulated to help consumers make a link between functional foods and health benefits.

In particular, consumers are gravitating toward foods and beverages with bright and exciting colors that indicate citrus flavors, with their naturally occurring vitamin C, as well as products with familiar, nostalgic flavors during these stressful times.

2. Sustainability takes center stageOver two-thirds (65 percent) of consumers want to have a positive impact on the environment through their everyday actions, according to ADM. This is a key reason why 32 percent of consumers buy sustainably produced items.

Specialized feed to reduce methane emissions in livestock, for instance, is helping to address consumer interest in more eco-friendly protein sources. New farming practices, such as regenerative agriculture, are being used to enrich soil, resulting in carbon drawdown and improvements to the water cycle.

Meanwhile, renewable plant-based materials such as cornstarch and even seaweed are appearing in consumer packaging to reduce landfill waste.

2. The gut microbiome emerges as the gateway to wellnessThe pandemic has accelerated consumer interest in a more holistic approach to health, which includes a greater understanding of the foundational role of the gut microbiome on each individuals health.

Click to EnlargeApproximately 25 percent of global consumers suffer from digestive health issues, ADM highlights.Approximately 25 percent of global consumers suffer from digestive health issues, ADM highlights. Of those, 50 percent claim that it has a moderate or severe impact on their overall health.

As consumers proactively seek foods and beverages that support a healthy microbiome, we are exploring new ways to incorporate probiotics into more challenging formulations such as dairy products and baked energy bars, Ferrell tells FoodIngredientsFirst.

Our HT-BPL1 is a postbiotic made from heat-treating the probiotic BPL1 that targets metabolic health. It is uniquely tolerant to high-heat applications and other harsh processing conditions like pasteurization commonly used in dairy foods and beverages.

Products targeting the microbiome have been shown to help address specific metabolic conditions and issues such as weight management, immune system support and better emotional well-being.

This provides fertile ground for food and beverage innovation with functional solutions like prebiotics, probiotics and postbiotics that support microbiome function.

4. Plant-based food boom expands beyond the bunGlobally, 56 percent of plant consumers are trying to eat more plant-based foods and beverages, pushing alternative proteins into an increasingly mainstream phenomenon.

Demand for plant-based protein products is rapidly expanding beyond just burger analogs to new and novel products, including alternative seafoods like shellfish and shrimp, plant-based cheeses, ready-to-eat protein snacks and more.

Alt-meat products also continue to evolve, with new technologies like 3D printing and protein fermentation playing a role in driving innovation. New plant-based meats on the horizon include whole-muscle products like steak and chicken breast, lunch meat, bacon and more.

The dairy alternative category, an early leader in the plant-based nutrition space, is growing to encompass other formats such as yogurt, ice cream, butter, spreads and creamers. To stand out in the dairy aisle, products must deliver more protein than traditional dairy, and feature a nutritional label fortified with vitamins and minerals or functional ingredients like probiotics.

5. Transparency builds consumer trustConsumers now expect food labels to provide greater transparency around the entire product life cycle. This is helping drive the demand for locally sourced products as consumers seek greater clarity on where the ingredients in food and beverages come from.

According to ADM, 26 percent of global consumers look for the country of origin on food and drink labels.

The quest for cleaner ingredients extends to flavors and colors, with many seeking natural alternatives, whether it be elderberries to give a product a rich blue hue or peppermint and mint to elicit an energizing burst of coolness in foods and beverages.

Sweeteners such as monk fruit and stevia are growing in popularity as consumers seek out natural ways to reduce their sugar intake.

Transparency was also crowned a the number one theme in Innova Market Insights Top Trends for 2021, released last month.

By Benjamin Ferrer

To contact our editorial team please email us at editorial@cnsmedia.com

If you found this article valuable, you may wish to receive our newsletters. Subscribe now to receive the latest news directly into your inbox.

More here:
ADM spotlights holistic health and beyond the bun plant-based developments in 2021 outlook - FoodIngredientsFirst

Nicole Junkermanns perspective on how technology could hold the key to living longer – Business MattersBusiness Matters

Posted on October 16, 2020 by Prof Baldwin

Many people take their health for granted, however, this crisis will surely encourage society to reassess its priorities and give importance to those things that are really essential.

Speaking at the Founders Forum Health Tech Summit at London Tech Week in September, The Health Secretary, Matt Hancock, announced a 140 million investment scheme to find and create new artificial intelligence (AI) programmes to improve patient health and care in the NHS. Mr Hancock spoke of three areas of focus for the NHS going forward: improving the environment of innovation, better use of data and changing the culture of the use of health technology. This scheme clearly underscores the fact that technology is at the centre of the Governments approach to health and life longevity.

Its not only the Government which is using technology to help us live longer, Silicon Valley tech giants are also utilising technology and AI in an attempt to extend the human lifespan. Notable technologies being developed include: implanting robotic muscles inside human bodies to help increase lifespan, the production of AI-powered drug discovery and the use of nanotechnology to place tiny machines into human blood streams and brains in the hope that they can free us of diseases.

I was a very early investor in both healthcare and biotech, particularly focusing on early-stage companies looking to utilise the latest advancements in technology to make much-needed breakthroughs in their fields. My focus when I first invested in this area was to support the companies on a mission to help people live both longer and healthier lives; and this remains my focus today.

Two of my portfolio companies are great example of how the right investor support can affect a real positive change in the healthcare field. The first is Gordian Biotech which has developed a pioneering platform capable of reducing the clinical testing times for the development of new drugs. The second is Cambrian Biopharma, a clinical-stage biopharmaceutical company founded in 2019 focused on developing therapies to prevent and cure age-related diseases with the help of AI. These examples are a testament to the powerful impact that meaningful investor support can have on these extremely valuable and innovative companies.

I also invest in products and ideas which help bring greater ease to peoples everyday lives, such as Elvie, (pictured above) co-founded by Tania Boler in 2014. The company has made great progress in developing products including the worlds first silent, wearable breast pump and the kegel pelvic trainer, which are making a real difference to the lives of women across the world. The company was one of the early pioneers of the rapidly growing Femtech sector.

Over the last decade, we have come leaps and bounds within the field of technology and innovation. Now more than ever, is it essential that we continue to invest in improving and developing technologies, as this truly is the key to health, longevity and fighting the current and any future pandemic.

Nicole Junkermann is an international entrepreneur and investor, and the founder of NJF Holdings, an international investment company with interests in venture capital, private equity, and real estate. Through NJFs venture capital arm (NJF Capital), Nicole oversees a portfolio similar in size to a small venture fund across Europe and the US, including in healthcare, fintech, and deep tech.

Follow this link:
Nicole Junkermanns perspective on how technology could hold the key to living longer - Business MattersBusiness Matters

US Pacific Presence: The Dark Side of the Compacts of Free Association – The Diplomat

Posted on October 28, 2020 by Prof Baldwin

In a recent International Center for Advocates Against Discrimination (ICAAD) report, a team of over 31 collaborating organizations worked to illuminate the inequalities resulting from the Compacts of Free Association (COFA). Drawing on history, policy, and legal analysis, they make the case that U.S. relations with the freely associated states are not benevolent partnerships, but one-sided agreements that are heavily influenced by the unequal power dynamics.

As the renewal negotiations commence, the international community must examine what economic assistance means in light of the decades of colonial destruction that has yet to be remedied. If the goal is to foster benevolent partnerships and to deserve a presence in the region, the United States must acknowledge and remedy this legacy of harm.

The COFAs are between the U.S. and three countries in the North Pacific: Micronesia (FSM), the Marshall Islands (RMI), and Palau. The key provisions of the agreements include U.S. military access and strategic denial; independent, self-governing status for the freely associated states; and economic assistance from the U.S.

The economic assistance for the FSM-RMI COFA is set to expire in 2023 which is why discussions about the negotiations have begun this year. Although there are many areas to explore in the negotiations, including compensation for the U.S. nuclear weapons testing program and health care access for COFA migrants in the U.S., Washington has set the terms narrowing the scope of the discussions to just the expiring economic provisions.

Get briefed on the story of the week, and developing stories to watch across the Asia-Pacific.

The issues related to the COFAs are complex and vary across the three states. Yet, the common COFA narrative describes the agreement in terms of U.S. military access in exchange for economic assistance and migration provisions. While we often hear about COFA politics through the lens of great power competition, ICAADs report unpacks issues related to human rights, migration, and environmental protection with a focus on the COFA provisions and policies that perpetuate inequities.

Enjoying this article? Click here to subscribe for full access. Just $5 a month.

The historical context of the COFAs is integral to understanding the current status quo. Across the region, military and strategic interests have always driven U.S. involvement even to the point of political meddling and regime change in Palau and empty and exploitative promises of self-sufficiency have resulted in dependency and neglect.

During the U.S. colonial administration over Micronesia, American leaders reported on the strategy to maximize U.S. interests in the region. They argued that increased economic assistance would guarantee the loyalty of the islands as a result of economic dependency.

While economic dependency on the United States was the central strategy to ensure the longevity of U.S. military access to the region, the U.S. position continues to tout self-sufficiency. However, for 40 years prior to independence, the policies of economic dependency undermined the freely associated states positions to become self-sufficient states.

The reality is that economic assistance never shifted to promote the political autonomy of the freely associated states in any meaningful way. While some have argued that the United States contributions to the freely associated states have been understated, others describe these contributions as mere payments in reciprocity for U.S. military benefits.

Economic anthropologist Jason Hickel makes the argument for changing the conversation in international development from aid offered to countries who have caused their own problems to reparations paid for the harm, extraction, and underdevelopment caused by colonization. This case is particularly strong in the North Pacific where colonization is underpinned by racism and American empire-building at the cost of lives, communities, culture, livelihoods, and the health of the environment.

The harm and destruction are clear in the Marshall Islands, where the United States tested nuclear weapons and land-grabbed atolls for strategic purposes. But it extends across the three freely associated states with climate inaction, the U.S., failure to protect COFA migrants from human trafficking, and the explicit exclusion of COFA migrants from federal benefits, including Medicaid, among other challenges explored in the report.

Not only is there ongoing harm perpetrated by the United States, but Washington has also been unwilling to acknowledge the damage. For example, if you look at the U.S. Embassy website, there is no acceptance of the full scope of responsibility for the nuclear devastation caused by the nuclear tests, which vaporized islands and uprooted entire communities from their homes.

Where the U.S. government has acknowledged responsibility, they have significantly narrowed the scope. For example, following the nuclear weapons testing program, compensation for land use and medical care was provided to only four atolls when the radioactive fallout impacted the entire country.

The United States is fond of describing its relations with the freely associated states as equal partnerships. However, a look at history and legal analysis of the COFAs and their related provisions tells a different story, one in which a conversation about reparations would be more appropriate.

Erin Thomas is the Policy and Research Coordinator at the International Center for Advocates Against Discrimination (ICAAD). Based in Auckland, New Zealand, she focuses on human rights in the Pacific Islands looking at gender-based violence, climate and nuclear justice, and international human rights law.

More here:
US Pacific Presence: The Dark Side of the Compacts of Free Association - The Diplomat

Investment opportunities being created as longevity research ramps up – BioWorld Online

Posted on October 4, 2020 by Prof Baldwin

The American Federation for Aging Research (AFAR) is involved in supporting research designed to unravel the biology of aging and expanding the field, and this week it held a webinar on the Business of Longevity: Moving Biomedical Advances into Biotech Opportunities. The Population Reference Bureau in its Population Bulletin projects the number of Americans ages 65 and older to almost double from the more than 52 million today to 95 million by 2060, and the 65-and-older age groups share of the total population will rise from 16% to 23%. The baby boomer generation (between ages 55 and 73) have raised challenges because aging is a strong risk factor for many chronic diseases that have become a major burden on the health care system. To respond to that situation, advancements in drugs, medical devices, diagnostics and digital health for the treatment of age-related conditions will be crucial. In addition, researchers are beginning to contemplate whether it will be possible to not only slow the aging process but also develop specific therapies to allow people to live healthier longer lives.

The panelists reviewed the latest research and looked at what it will take to attract more investment and biotech companies into what remains a nascent area but one that offers tremendous commercial opportunities.

One of the participants, Mehmood Khan, CEO of Boston-based Life Biosciences, said longevity research has been accelerating over the last decade. However, new talent and companies still need to be attracted into the sector.

Jim Mellon, chairman of Juvenescence Ltd., noted aging research is still at the dial-up stage of the internet in terms of progress. To kickstart the field, product successes are needed. Unfortunately, some commercial forays have hit roadblocks.

Most recently in August, Unity Biotechnology Inc. reported UBX-0101, a senolytic p53/MDM2 interaction inhibitor, intended to act by eliminating senescent cells and inducing cartilage regrowth for the potential intra-articular treatment of inflammatory joint disease, failed to best a placebo on an established measure of osteoarthritis (OA) pain in a phase II study.

The San Francisco-based company has now shifted its focus, announcing a restructuring last month to align its resources on cellular senescence programs in ophthalmology and neurology. It said it will advance UBX-1325 to phase I development in patients with diabetic macular edema and expects to dose the first patient later this year.

The compound targets Bcl-xL, a novel mechanism to eliminate senescent cells in age-related diseases of the eye. The UBX-1325 study in diabetic macular edema is expected to begin before the end of the year. In an announcement, Unity said it will also focus on senolytic therapies for neurological diseases as well as exploring novel mechanisms for cognitive benefit. The company said it will extend its cash resources by making a 30% cut in its workforce.

Unitys disappointing trial results followed the failure of Restorbio Inc.'s PROTECTOR 1 phase III study designed to evaluate RTB-101 in preventing clinically symptomatic respiratory illness (CSRI) in adults ages 65 and older. RTB-101 is an oral, selective target of rapamycin complex 1 inhibitor.

The failure led the companys board to examine its strategic alternatives that eventually culminated in a merger with Adicet Bio Inc., with the combined company focusing on Adicets off-the-shelf allogeneic gamma-delta T-cell therapies for oncology, with its lead candidate, ADI-001, a gamma-delta CAR T-cell therapy targeting CD20 being developed for non-Hodgkins lymphoma.

New long-term trial

Interest will also focus on the long-term study of FDA-approved drug metformin that has been used to treat diabetes for more than 60 years. The compound has also been implicated in slowing aging in model organisms and reducing the incidence of aging-related diseases. According to AFAR scientific director Nir Barzilai, metformin is being tested in the Targeting Aging with Metformin (TAME) trial that will involve 3,000 individuals between the ages of 65 and 79. The NIH-funded Geroscience Network recommended metformin because of its safety and low cost. Several studies will test whether those taking metformin experience delayed development or progression of age-related chronic diseases such as heart disease, cancer and dementia.

Barzilai noted that several other good candidates for age-related diseases have emerged from the National Institute of Agings ongoing Intervention Testing Program, a multi-institutional study investigating treatments with the potential to extend lifespan and delay disease and dysfunction in mice.

Other recent developments

Douglas, Isle of Man -based Juvenescence said it established Juvenomics Ltd., a joint venture with G3 Therapeutics Inc., of Midlothian, Va., that will focus on developing validated nutraceuticals and medicines to combat aging and aging-related diseases such as those of the musculoskeletal system. Juvenomics is built on the combination of G3s multi-omic biological dataset, consisting of trillions of datapoints collected in the global clinical study of more than 7,500 patients, and the machine learning platforms assembled by Juvenescence.

Agex Therapeutics Inc., of Alameda, Calif., a biotechnology company developing therapeutics for human aging and regeneration, and Pluristyx Inc., of Seattle, have signed a manufacturing, marketing and distribution agreement through which Pluristyx will undertake those activities on behalf of Agex with respect to Agexs research and clinical-grade ESI brand human embryonic stem cells. The agreement builds on Pluristyxs strategy with standardized Ready-to-Use brand and Ready-to-Differentiate pluripotent stem cells to industry and academic scientists working on developing therapeutic products to treat human disease, the company said.

Grifols SA, of Barcelona, Spain, said it will acquire Alkahest Inc., of San Carlos, Calif., to enhance discovery and R&D to identify therapies for age-related diseases based upon an understanding of the human plasma proteome for $146 million. The transaction is expected to close early next year. In addition to the clinical development of specific plasma fractions and protein inhibitors, Alkahest said it is focused on developing a complete understanding of the human plasma proteome.

Foster City, Calif.-based Geron Corp., which is developing a first-in-class telomerase inhibitor targeting hematologic myeloid malignancies, established a loan facility this month for up to $75 million with Hercules Capital Inc. and Silicon Valley Bank. The companys imetelstat development program includes two registration-enabling studies, IMerge, an ongoing phase II/III trial in lower-risk myelodysplastic syndromes (MDS), and a planned phase III trial in refractory myelofibrosis expected to be open for patient screening and enrollment in the first quarter of next year.

Cohbar Inc., of Menlo Park, Calif., which is developing mitochondria-based therapeutics to treat chronic diseases and extend healthy lifespan, closed its underwritten public offering of 12.3 million units, consisting of one share and one warrant to purchase 0.75 of a share of common stock at an exercise price of $1.44, priced at $1.22 each. The underwriters partially exercised the overallotment option for warrants to purchase an additional 1.38 million shares. The gross proceeds were approximately $15 million. In August, the company reported that the first subjects had been dosed with CB-4211 in the phase Ib stage of its phase Ia/Ib trial for NASH and obesity. The study is designed to assess the potential effects of CB-4211 on liver fat, body weight and various biomarkers that are relevant to NASH and obesity.

San Diego-based Deep Longevity Inc., a company focused on artificial intelligence for aging and longevity research, is being acquired by Regent Pacific Group Ltd., of Hong Kong, for HK$29.56 million (US$3.8 million). The company came out of stealth from Insilico Medicine, of Rockville, Md., in July. It also reported the launch of the first AI system on the market for aging-related biomarker development and a collaboration with San Diego-based Human Longevity Inc. The company said it has developed a new AI system that can predict an individuals biological age more accurately vs. conventional methods, paving the road to discover what biological culprits drive aging-related diseases.

Immetas Therapeutics Inc., of East Hanover, N.J., has raised $11 million from a series A financing to advance research on inflammation pathways in aging and the development of immune-modulating treatments for cancer and inflammatory disease. The companys lead program is aimed at designing a series of bispecific antibodies to regulate inflammation in the tumor microenvironment and overcome resistance to conventional immune checkpoint therapies.

More:
Investment opportunities being created as longevity research ramps up - BioWorld Online

Government enters into contract with Abingdon Health for COVID-19 antibody test – Pharmafield

Posted on October 8, 2020 by Prof Baldwin

The UK Government has entered into a contract with Abingdon Health, on behalf of the UK-Rapid Test Consortium (UK-RTC), for the supply of the AbC-19TM Rapid Antibody tests. As part of the contract the UK Government has placed its first order for one million COVID-19 rapid antibody tests.

This follows an independent evaluation commissioned by the UK government of the AbC-19TM Rapid Antibody test, which will be published in full in due course by Public Health England (PHE), after peer review.

The AbC-19TM Rapid Test, uses a small drop of blood from a finger-prick, and shows results in 20 minutes, without the need to go to a specialised laboratory. It detects IgG antibodies to full trimeric spike proteins of the SARS-CoV-2 virus. This means the test detects those antibodies which interfere with the viruss ability to enter the human cells.

The test can be administered by healthcare professionals, such as doctors, nurses, pharmacists and healthcare workers, at the point-of-care. It has already received the CE mark, which indicates health and safety conformity for goods sold in the UK and EU.

The test will make it possible to build a swift and clear picture of how the virus has spread throughout the UK population.

It will also be able to help establish the effectiveness of any vaccine which provides protection by creating new antibodies. This information will be critical to managing current and future outbreaks of COVID-19.

Mass production is already under way and the antibody test will be rolled out under the governments COVID-19 surveillance studies to help build a picture of how the virus has spread across the country. Surveillance studies are vital to develop our understanding of how antibodies work. The antibody test has been developed for the Department of Health and Social Care in response to the Governments need to procure a high-quality antibody test.

To develop and mass produce the volumes needed for the UK population, Abingdon Health set up and led the UK-RTC in April this year. The consortium brings together the UKs largest rapid test medical manufacturers, working together to provide capacity for delivery of more than a million tests per week.

Abingdon Health CEO Chris Yates said: Our test will help give a picture of how many people in the UK have antibodies. This will be a crucial part of the understanding of immunity to COVID-19.

Mass testing will also help understand what the longevity of immunity is and, in time, help assess the efficiency of any vaccine on the market. In this respect, high-quality mass antibody testing has never been more important, and it will be critical for future public health responses.

The UK Government order of the first one million tests is an endorsement of this UK designed, developed and manufactured high-quality rapid diagnostic test. It is a triumph of British business and a breakthrough for UK life sciences.

We have ramped up production since the start of August and will be ready to deliver the first tests to the Government by early October. I would like to express my thanks to all my Abingdon Health colleagues for their tremendous support and hard work in achieving this milestone.

Health Minister Lord Bethell said: This home antibody test developed by our outstanding British scientists and researchers at the UK Rapid Test Consortium will provide critical insight into how the infection has spread, growing our understanding of coronavirus so that we can better respond to it.

Global Precision Medicine Software Market 2020 One the most booming industry in forthcoming years due to worldwide demand in Coronavirus (COVID-19)…

Posted on October 4, 2020 by Prof Baldwin

Global Precision Medicine Software Market: Industrial Analysis, Supply And Demand Analysis, And Future Market Trends

GlobalPrecision Medicine Software marketreport offers apoint by point analysis of the major trends, opportunities, restraints, and growth factors of the market.Market Data Analyticshas published a report on Precision Medicine Software market to give a brief idea about the market scenario on the global and regional platform. Furthermore, the report incorporates the crucial factors that helpescalate the CAGR during the forecast timeframe as the future scope and application are growing at a rapid pace on the global scale. Precision Medicine Software market report has the details of segmentation, application, regions, key players, and other segments provided in an elaborative manner. Additionally, the regional players North America (U.S., Canada, Mexico), South America (Cuba, Brazil, Argentina, and many others.), Europe (Germany, U.K., France, Italy, Russia, Spain, etc.), Asia (China, India, Russia, and many other Asian nations.), Pacific region (Indonesia, Japan, and many other Pacific nations.), Middle East & Africa (Saudi Arabia, South Africa, and many others.) are found to have a massive impact on the market share growth and share.

Get Exclusive PDF Sample Copy Of This Report@https://www.marketdataanalytics.biz/global-precision-medicine-software-market-industry-trends-and-forecast-27207.html#request-sample

Overall market investment scenario is very well incorporated in the Precision Medicine Software market report. Even though the current COVID-19 pandemic continuous the report provides complete 360 degrees of analysis from sales chain, import and export channels to regional government policy and future scope on the industry. A detailed analysis of the market status, competition pattern among the key players, advantages & disadvantages of enterprise products, industry development scope, regional industrial blueprint characteristics and macroeconomic policies, industrial policy has also been covered in the Precision Medicine Software report. At the same time, the key playersSyapse, Allscripts, Qiagen, Roper Technologies, Fabric Genomics, Foundation Medicine, Sophia Genetics, PierianDx, Human Longevity, Translational Software, Gene42, Inc, Lifeomic Healthhelp gets hands on the market status and revenue on a global platform. Furthermore, only after scientific analysis the raw materials and end users of this industry coupled with the trends of product distribution and sales channel are offered as well. Bearing in mind COVID-19, this report gives comprehensive and in-depth analysis on how the pandemic has helped the entire industry transform and reform.

Product Type analysis:Cloud-based, On-premise

Application analysis:Healthcare Providers, Pharmaceutical and Biotechnology Companies, Research Centers and Government Institutes, Others

Complete report information along with sample/table of contents available::https://www.marketdataanalytics.biz/global-precision-medicine-software-market-industry-trends-and-forecast-27207.html

Key objective of this report:

Overall growth aspects of the global Precision Medicine Software market Overview of leading companies, market strategies, and market growth factors Historic, current, and future market scope Market drivers, restraints, and opportunities Key trends, new investment projects, and key market statistics

Factors covered in the report:

Competitive landscape Market shares and revenue, product pricing, demand and supply, growth rate, future scope, and technological developments Panorama of industrial developments Regional dynamics Market growth drivers

Place Inquiry for Buying or Customization of Report:https://www.marketdataanalytics.biz/global-precision-medicine-software-market-industry-trends-and-forecast-27207.html#inquiry-for-buying

About Us

Market Data Analytics is a leading global market research and consulting firm. We focus on business consulting, industrial chain research, and consumer research to help customers provide non-linear revenue models. We believe that quality is the soul of the business and that is why we always strive for high quality products. Over the years, with our efforts and support from customers, we have collected inventive design methods in various high-quality market research and research teams with extensive experience.

Continue reading here:
Global Precision Medicine Software Market 2020 One the most booming industry in forthcoming years due to worldwide demand in Coronavirus (COVID-19)...

Longevity Project: Panelists discuss what it takes to overcome life’s challenges – Aspen Times

Posted on October 4, 2020 by Prof Baldwin

Sean Swarner treks to the North Pole in spring 2017. Swarner, a two-time cancer survivor with one functioning lung, also has been to the South Pole and completed the Seven Summits in addition to other athletic achievements.Courtesy photo

Show CaptionsHide Captions

Part of being human is finding courage to stay the course when life wants to go in a different direction. Paralympic snowboarder Noah Elliott knows all about overcoming those challenges after he decided to have his leg amputated so he could pursue sports again.

No matter who you are, you experience an I cant moment in your life, Elliott said. Although its hard to see, those I cant moments are the moments that define you as a person and define your next chapter.

Elliott, who currently serves as the outreach program director for Steamboat Adaptive Recreational Sports in Steamboat Springs, was one of four guest speakers who took part in a virtual panel Tuesday as part of the annual Longevity Project, which was moderated by Aspen Times editor David Krause.

Other guests included Dash Doung Wong, a cancer survivor who now lives in Aspen; Nick Isenberg, a blind and partially deaf journalist who lives in the Roaring Fork Valley; and Kailyn Forsberg, a former freeskier from Eagle whose life and career took a turn when a crash during a slopestyle warm-up left her lower body paralyzed.

The Longevity Project a four-part editorial series that includes two virtual events focuses on living well in the mountains. A major theme of Tuesdays panel was learning to overcome lifes most difficult obstacles.

Having a great support system off the bat was definitely something that encouraged me to push as hard as I could. Without that, I dont believe I would have been able to be where I am today, Forsberg said of her injury five years ago before reflecting on her first time getting to sit ski at Winter Park. There were emotional boundaries there. I was so curious about the physical limitations I would have. But just sitting there when they got me all set up in the sit ski, I was just like, This is what I love to do. And Im not going to let an accident just stop me from doing things I love.

Earlier this spring, Wong had to fight off a bout with COVID-19. He said hes back to 100% although the disease did leave his only lung scarred. His other lung was removed because of cancer and that decision was a difficult one for Wong, who knew he would be giving up his military career. He had spent more than a decade as a Navy SpecOps before being medically discharged. He now devotes much of his time to veteran causes.

As part of our annual Longevity series, The Aspen Times, Glenwood Springs Post Independent, Steamboat Pilot and Vail Daily are hosting a panel of inspiring people who have fought through adversity and continue to thrive in the mountains. Hear how they have fought off cancer, paralysis and blindness and continue to live a full, grateful life.

The only I cant do this moment was when I had to choose to remove my lung. It was a choice I had to make, whether I was going to fight cancer through other means or if I was going to go with the surgical route, Wong said. I put so much of my identity and who I was into my job or my work, where it became everything of me. And because of a certain event that happened to me, all of it was taken away. That was the most destructive thing that could have ever happened to me and I was left in a dilemma of trying to figure out, Who am I?

When it comes to overcoming lifes most difficult challenges, each of the panelists talked about putting focus on what one can do, as opposed to what one cant do. Despite not being able to see, Isenberg has found a way to empower the blind through his radio series, The Tactile Traveler. Elliott works with children who are dealing with similar physical challenges, and Forsberg continues to move forward despite barely being able to move at all.

That just puts you in the mindset of negativity and things you are not going to be able to do. But if something happens, you just have to take it one day at a time, Forsberg said of dealing with simple things, such as not being able to go on hikes with her friends. There is no point in wallowing in the fact I cant do what they are doing. I have to look forward and look at myself and do the things I can still do.

The Longevity Project will conclude Wednesday with its second virtual event, a talk with keynote speaker Sean Swarner, the first cancer survivor to have summited Mount Everest. The free discussion begins at 6 p.m. Viewers can register ahead of time at aspentimes.com/longevity.

The Longevity Project is being produced in partnership with The Aspen Times, Summit Daily, Glenwood Springs Post Independent, Steamboat Pilot & Today and Vail Daily.

acolbert@aspentimes.com

Read the original:
Longevity Project: Panelists discuss what it takes to overcome life's challenges - Aspen Times

How does the human body react to being in space? – Sciworthy

Posted on December 22, 2020 by Prof Baldwin

Since 1961, more than 500 humans have flown into space. However, only 20 astronauts have stayed more than 90 days on long-duration space missions. If humans will one day travel to and from Mars, the round-trip will take 3 years. It is essential then, before those crew members ever launch, that we understand the effects long duration spaceflight has on the human body.

This unique environment consists of extreme conditions such as weightlessness, high radiation, variations in extreme temperature and pressure, among other health stressors. Long duration space flight significantly affects astronaut body mass index and what genes are expressed. Changes in metabolism, vascular health, the gastrointestinal microbiome, and cognitive performance were also observed during spaceflight. These adverse effects resolve upon return to earth as astronauts maintain vigorous exercise and nutrition programs for rehabilitation.

To study in depth the changes taking place in the human body over such a long mission in space, researchers need to look at everything from genetics to body mass. Among the Astronaut corps, NASA had a unique opportunity a set of genetically identical twin astronauts, Scott and Mark Kelly. For 340 days, Scott would be on the International Space Station (ISS), while Mark remained on Earth, both undergoing the same medical analyses, pre-flight, in-flight, and post-flight to catalog the changes between the two.

The results were obtained from samples including saliva, stool, skin, urine and blood. Different molecular level techniques, cognitive tests, and biometric tests were used to understand the genetic, physiological and psychological changes in the astronauts.

The astronauts experienced changes in the expression of over 800 genes during spaceflight. Most of the genes returned to normal after flight, but some did not leading to changes in astronauts genetics and physiology. Space radiation may have damaged their DNA.

The midflight flu vaccination administered by the astronauts worked exactly as it does on Earth. This suggests the primary immune system functions were maintained during the flight, and vaccines were still an effective tool for protection.

Genes related to inflammation were more active, which may result from the human body reacting to long duration space flight. Researchers suggest telomeres (a region of DNA at the end of a chromosome) act as an aging clock in every cell, as we grow older our telomeres grow shorter. Telomere elongation was observed in space, but we cannot conclude that space is a miraculous location that adds to human longevity. Elongation may be due to the exercise and calorie-regulation astronauts maintain inflight.

A rapid shortening of telomeres in less than 45 hours was observed upon astronaut return to Earth, likely due to the extreme stresses associated with landing. Mainly the longer telomeres are associated with healthy lifestyle factors such as good nutrition and regular physical activity. However, it is unknown if telomere lengthening and shortening relate to aging in this case, because of the lack of research conducted on telomeres in microgravity.

Spaceflight might have effects on learning and cognition. The in-space astronaut could complete learning and work tasks with greater speed and accuracy, concluding that spaceflight may affect cognition positively.

Bone density is of great concern for space biology researchers. It is well known that spaceflight causes rapid loss of bone density, decreased muscle mass, and weight loss. These are common physiological changes observed in astronauts due to changes in gene and hormone regulation in space. Furthermore, due to microgravity, blood and fluids move from lower to upper body called headward fluid shift causing an appearance of a puffy face and skinny legs. This fluid shift may lead to increased pressure in the veins and capillaries of the eyes causing vision problems in astronauts.

Research also suggests astronauts are at high risk for dehydration, evidenced by changes in the gene AQP2, which regulates water reabsorption in the body and is a useful indicator of hydration status. On the ISS, the isolated and confined environment of the astronauts puts them in a degree of psychological stress. Meanwhile, eating only freeze-dried or heat-stabilized prepackaged food in space is different from what astronauts are used to eating on Earth. These psychological and nutritional stressors in astronauts negatively affect the function of beneficial gut microbes. This change in the gut microbiome results in alterations of immunity, physiology, and even psychological well-being.

The NASA twin study generated unique biomedical data on the effect of a year-long spaceflight on the human body. Most of the biological changes returned to baseline after the 340-day space mission, suggesting that human health can be mostly sustained over this spaceflight duration. As the researchers suggest, the space environment leads to potential health risks. Exercise, a good diet, and personalized medicine will make multi-year space exploration safe for astronauts. These advancements also have the potential to improve Earth medicine as well.

Read this article:
How does the human body react to being in space? - Sciworthy

Cooking lessons and more with OSU Extension | News | sent-trib.com – Sentinel-Tribune

Posted on October 4, 2020 by Prof Baldwin

OSU Extension Wood County is offering virtual classes.

Wednesday, noon-12:45 p.m. - The Mediterranean Diet: The Mediterranean Diet has been a subject of intensive research for more than 50 years. The evidence of this diets health benefit is compelling. Attend this workshop to understand how to apply this eating style to your family meals.

Oct. 14, noon-12:45 p.m.- Cooking with Quinoa: Learn about the health benefits of this economical food. This program will focus on the benefits of this food in the diet, how to cook quinoa and recipes to try at home.

Oct. 28, noon-12:45 p.m.- Beating the Blues: Did you know Seasonal Affective Disorder affects about 6% of Americans; however, as many as 15% of people in the U.S. may have a milder version that includes only some of the symptoms, often referred to as the winter blues. Attend this session to Identify symptoms of winter blues, learn tips for beating the winter blues and set some goals to beat those winter blues.

Nov. 4, noon-12:45 p.m.- Seasonal Eating for people with Diabetes: November is National Diabetes Month, and with 34 million Americans who h have diabetes, this time of year can be more difficult to manage. Take Charge of Your Diabetes during the Holidays will provide you with tips for managing your diabetes during the holidays. You will learn how to prepare favorite holiday foods that are both nutritious and delicious

Nov. 10, noon-12:45 p.m.- The Mediterranean Diet Part 2: In this workshop, we will expand on the Mediterranean Diet, and build on the information from the first session. Mediterranean Diet part 1 is a prerequisite to register for this class. Learn more about the study of the 5 blue zones, which are longevity hot spots around the globe. Participants will learn what centenarians eat to live to the age of 100 and beyond. Participants will be asked to complete a brief pre-survey to ask how are following the Mediterranean diet and we will discuss it during the presentation.

Nov. 18, noon-12:45 p.m.Be Savvy with your Spirits: The average American sees an increase in their alcohol drinking habits between Thanksgiving and New Years. This session will discuss the recommendations for alcohol consumption, health implications of various drinking patterns. Participants will also learn how alcohol may impact weight, diabetes, hypertension and heart disease.

Nov. 24, noon-12:45 p.m.- Nutritions Role in a Healthy Microbiome: In this workshop you will learn the important role the human microbiome plays in human health as it relates to metabolism, immunity development, nutrition, and its link between various diseases. We will explore tips to nourish our human microbiome through the foods we choose in order to fuel our body. We will also discuss the difference between prebiotics and probiotics

Dec. 2, noon-12:45 p.m.- Humor and Stress: This session will focus on the humor and stress management techniques. This session will discuss research on stress on the body as well as the role humor can play in reducing stress. Laughter is good medicine!

Dec. 9, noon-12:45 p.m.- Aging and your Brain Health: Researchers say that living a mentally active life, is just as important as living a physically active life. This session will discuss the health benefits of brain workouts, provide examples of brain exercises.

Dec. 16, noon-12:45 p.m.- Seasonal Eating for people with Diabetes: November is National Diabetes Month, and with 34 million Americans who h have diabetes, this time of year can be more difficult to manage. . Take Charge of Your Diabetes during the Holidays will provide you with tips for managing your diabetes during the holidays. You will learn how to prepare favorite holiday foods that are both nutritious and delicious

Doubting Tom Bradys longevity never ages well – Maize n Brew

Posted on October 4, 2020 by Prof Baldwin

Tom Brady is 43 years old now, and in some ways his age is showing. His hair is a little more salt and pepper than it once was, theres a few more wrinkles here and there, his legs arent as nimble. Entropy happens to us all.

Tom Brady is also a 43 year old who has one of the best diets a human can have and still plays the game of football at a high level. The now Tampa Bay Buccaneers quarterback is the greatest QB of all time. With 6 Super Bowl rings and 9 appearances overall, thats a topic that shouldnt even be a discussion present day. Even when youve received all the accolades of yesteryear like Brady has, he still has to continuously prove himself once more.

Just like most times in his career when he struggled, Brady battled back. He turned things around during the game. The Bucs faced a 17-point deficit, but being behind by that score isnt something that is going to make Brady put his head down. Instead, Brady ended up having one hell of a second half. Brady completed 15 of 17 passes in the second half for 263 yards, 3 touchdowns with a perfect 158.3 passer rating. The Bucs won 38-35. Brady threw 5 touchdowns to 5 different receivers, the first time hes done that in a game in his career.

Bradys passes still have a lot of zip on them, he can still deliver an accurate deep ball. His mental prowess is unparalleled. Hes Tom effin Brady. Not much has changed. Hes still someone you dont want to go toe-to-toe with in Week 4, and definitely not in the playoffs.

Its quite hilarious to see some of the narratives play out when Brady makes any error. Those reactions tend not to age well. Weve seen this for the better part of a decade now, and Brady keeps proving doubters wrong. Beyond Bradys love for the game, the fact he still has to prove himself is reason enough for him to keep playing.

In a relatively weak looking NFC, Brady and the Buccaneers have a realistic shot at making the Super Bowl. With that in mind, now would be a good time to stop doubting Tom Brady and his longevity. Instead, appreciate greatness and look into what the hell hes doing to stay so physically fit and healthy. The TB12 method seems to be working.

Tigerlily Foundation to Lead Historic Special Session on Health Equity, Collaboration and Partnership at the 2020 San Antonio Breast Cancer Virtual…

Posted on December 5, 2020 by Prof Baldwin

Tigerlily Foundation co-hosts this historic special session in collaboration with the American Association for Cancer Research (AACR), titled Setting the Stage for Health Equity, Collaboration and Partnership, on December 8, 2020, to discuss continued collaborative action towards health equity in breast cancer care, at SABCS 2020. The event is designed to foster transformational dialogue and lead to specific strategies to end barriers at every level of healthcare for people of color.

Washington, DC, December 05, 2020 --(PR.com)-- Tigerlily Foundation, a national breast cancer organization established by a Black, first-generation immigrant woman and patient-led organization will open the San Antonio Breast Cancer Symposium (SABCS). Maimah Karmo, President and Founder of the Tigerlily Foundation, has set the stage for a new day, as she has raised the bar higher in health equity, taking the stage as the first Black patient leader to co-host the opening special session at this global scientific conference. Although the path to representation and being on an equal playing field as scientists and researchers has been long, particularly as a woman of color, Karmo knew that the road to health equality and justice takes time; and in the midst of racial injustice, a global pandemic, and heightened disparities faced by people of color, the time was now to set and take the stage to usher in a new day.

Maimah Karmo and Dr. Chuck Perou, Professor of Genetics, LCCC Member, and Co-Director of the Computational Medicine Program at the University of North Carolina will co-host this session, with some of the most globally renowned scientists of color. Shawn Johnson, a medical student at Harvard Medical School will make a special presentation on the history of how racism, redlining, segregation, and institutional policies affects healthcare; followed by three presentations - by Dr. Lisa Newman surgical breast oncologist and Chief of the Section of Breast Surgery, and a physician scientist of Weill Cornell Medical College; Dr. Funmi Olopade, a breast medical oncologist and physician-scientist, and is a pioneer in cancer genetics, and the Walter L. Palmer Distinguished Service Professor of Medicine and Human Genetics and Director of the Center for Clinical Cancer Genetics and Global Health from the University of Chicago; and Dr. Maria Elena Martinez of UCSD, a Professor in the Herbert Wertheim School of Public Health and Human Longevity Science, who holds the Sam M. Walton Endowed Chair for Cancer Research and Co-leads Community Outreach & Engagement at the Moores Cancer Center.

This session builds on Tigerlily Foundations innovative and patient-first approach to engaging patients of color, and its historic Young Womens Metastatic Breast Cancer Disparities Fireside Chat, where Tigerlily Foundation brought the largest contingency of Black women to the conference, to host a conversation centered on understanding the gaps, misperceptions and barriers within the healthcare system that affect young women of color with metastatic breast cancer (MBC).

The 2020 SABCS special session will highlight this year's achievements Tigerlilys national MBC ANGEL Advocacy Training which educated women of color living with metastatic breast cancer and living in the 20 cities with the highest mortality rate of breast cancer; a COVID-19 Relief Program; a myriad of virtual on-line and COVID-safe in-personal activations in communities of color to provide education and access to screening; engagement of thousands of advocates nationwide; monthly bi-directional conversation series, between Black patient experts and non-Black healthcare professionals; and more than 400 million social media impressions from social and mainstream media focusing on health disparities, and directly impacting countless patients in local, national and global communities.

Most notably, Tigerlily Foundation launched the #inclusionpledge which provides a transparent and tangible framework across stakeholder sectors to identify and track equity actions, holding anyone accountable who through action or inaction impacts the lives of women of color to make specific and measurable change to improve outcomes for Black and Brown women.

For this Tigerlily Foundation and AACRs Special Session, Setting the Stage for Health Equity, Collaboration and Partnership, partners and attendees are invited to use their privilege for power by taking the #inclusionpledge.

At the 2019 SABCS, several advocates made an #inclusionpledge to only participate in advocacy initiatives panels, advisory boards, planning committees, programs - that include the experience of Black women. This year, the pledge has expanded and is a rallying cry and call to action, as Tigerlily Foundation encourages leaders in the breast cancer care ecosystem - pharmaceutical companies, clinical research organizations, clinicians, healthcare systems, healthcare payor systems and physician organizations and groups - to stand up and join those efforts with their own specific actions we can take now to help end disparities. Visit Tigerlily Foundation #InclusionPledge for Black Women to learn how you can collaborate on these efforts.

Race, literacy, financial barriers, access, social, systemic and hereditary backgrounds should not be determinants of life and health equity. To continue to accelerate impact as it relates to disparities and women of color, the #inclusionpledge is imperative. As an organization, Tigerlily Foundation was founded to address inequity of age, of stage and of color. We must see that health disparities is a racial justice and civil rights issue and work to end this injustice. Never again should there be health meetings without Black patients on the stage, providing real world input. There have been no ramifications for healthcare systems that has hurt when meant to heal, but one in which patients of color face unequal health treatment, limited access to clinical trials, unconscious bias and microaggressions - patients who the healthcare system has taken an oath to protect. This is the reality of living with cancer while being Black. If the global community could unite to develop three vaccines for COVID-19 in six months, eliminating all barriers to healthcare is possible. We can change this by enacting anti-racist policies across the globe and checks and balances to combat discrimination throughout every aspect of our healthcare system. We must have vulnerable, heart-based conversations, and healing on both sides. Being Black should not negate our right to live. The murder of George Floyd unveiled the inherent disregard for Black peoples lives. It is incumbent on all, especially those whose privilege allows for oppression of others, to use that privilege to end barriers. We launch the #inclusionpledge to advocate for and activate the inclusion of women of color across initiatives impacting their breast and overall health. Maimah Karmo, President, Tigerlily Foundation

This Special Session at the SABCS meeting is critically important and represents a step forward towards the goal of providing equitable health care to all. We are directly talking to the right audience, which represents thousands of cancer health care providers from around the world, and these are the people who can enact change. To accomplish this goal, we will discuss many of the possible causes of health care outcome disparities, be they societal or biological, and plan to identify solutions that will bring us closer to a level health care playing field. Charles M. Perou, PhD, The May Goldman Shaw Professor of Molecular Oncology

Im proud to be a part of this powerful session, where Tigerlily Foundation and the San Antonio Breast Cancer Symposium have partnered to create a landmark program of presentations highlighting the multi-factorial nature of breast cancer disparities. This session will feature groundbreaking research regarding the cascade of influences - ranging from socio-economics and systemic racism, to tumor biology and genetics - all of which converge to result in the 40% higher breast cancer mortality rates observed in African American compared to White American women. This session goes even further with groundbreaking discussion of how policy and advocacy can be leveraged to address and reverse these disparities, and the importance of true collaboration with patients as experts. Dr. Lisa Newman, Weill Cornell Medicine

The special session taking place at SABCS is important. Disparities in breast cancer care and survival outcomes for Black women have to be addressed now. It's time to shift the paradigm from limited narratives about socioeconomic status and poverty and bring attention to structural racism and provider bias that impacts the breast cancer care and survival of Black women. Jamil Rivers, Founder and CEO of The Chrysalis Initiative

This session will be aligned with a Twitter activation, which coincides with the graduation of his event is generously supported by AmGen, Athenex Oncology, Daiichi Sankyo, Immunomedics, Sanofi, SeaGen, Lily Oncology, Merck and Pfizer, and in partnership with the Iris Collaborative.

Event Information:Title: The SABCS Special Session - Presented by Tigerlily Foundation & AACRPoster Spotlight Sessions and Panel Discussions on Setting the Stage for Health Equity, Collaboration and Partnership (Panel Discussion, Twitter Chat and Facebook Live)Date/Time: December 8, 2020, 8:15a.m. 11:00 a.m. CSTLocation: Virtual Symposium, San Antonio, TexasRegister: https://www.sabcs.org/2020-SABCS-sup-sup/SABCS-sup-sup-Registration-VirtualContact: Email inclusionpledge@tigerlilyfoundation.org to interview participants at SABCS or in their local communities, or for more information on media, partnerships or sponsorship opportunities.

Contact Information:Tigerlily FoundationMamah Karmo888-580-6253Contact via Emailwww.tigerlilyfoundation.org

Read the full story here: https://www.pr.com/press-release/826753

Press Release Distributed by PR.com

Lazard Asset Management expands thematic investment offering with new healthcare team – Institutional Asset Manager

Posted on October 28, 2020 by Prof Baldwin

Lazard Asset Management (LAM) has added Ryan Hutchinson and Stefan Wimmer to the firm along with their Digital Health investment strategy.

Hutchinson, Director and Portfolio Manager, and Wimmer, Senior Vice President and Portfolio Manager are based in New York and Berlin, respectively.

Stefan and I are looking forward to having the ability to contribute to and leverage LAMs global investment platform, while benefiting from the firms data science tools, its best-in class infrastructure and its distribution capabilities.The Digital Health Strategy is a concentrated, unconstrained, thematically driven equities strategy focused on the multi-disciplinary disruption of the healthcare ecosystem. The team invests in companies that are positioned to benefit from the technological transformation of healthcare. Among other things, the team looks for companies involved in the increased digitalisation and personalisation of healthcare activities which are poised to improve consumer experience, reduce cost burden, raise the quality of life, and ultimately increase human longevity."Ryan and Stefan bring a wealth of knowledge and experience to our global research platform, says Nathan Paul, Chief Business Officer, LAM. The team will help us further our efforts to offer our clients the thematic investment solutions that they are looking for in this macro-economic environment.Both Hutchinson and Wimmer previously worked at Global Thematic Partners, where they served as lead portfolio managers of the Digital Health Strategy.We found a strategic and cultural fit at LAM, where fundamental investment research is central, ESG is integrated, and there is a true appreciation for thematic investing, says Hutchinson. Stefan and I are looking forward to having the ability to contribute to and leverage LAMs global investment platform, while benefiting from the firms data science tools, its best-in class infrastructure and its distribution capabilities.

Originally posted here:
Lazard Asset Management expands thematic investment offering with new healthcare team - Institutional Asset Manager

Ciara and ex-Lululemon CEO launch new clothing brand with ‘more to it than fashion’ – CNBC

Posted on December 5, 2020 by Prof Baldwin

Grammy Award-winning artist Ciara has launched a new fashion company alongside her husband, NFL star Russell Wilson, and former Lululemon CEO Christine Day. But the brand, called the House of LR&C, has a mission beyond just the clothes it sells, Ciara and Day told CNBC on Wednesday.

"We're not only doing the fashion part. We're also combining the passion for fashion but also the passion for impact. That was really important to both Russell and I and also Christine in creating our company. There has to be more to it than fashion," Ciara said on "Closing Bell."

In addition to an emphasis on environmental sustainability, 3% of each purchase goes to the Why Not You Foundation, which Wilson founded in 2014. It supports efforts on education access, poverty reduction and children's health.

Day, who left Lululemon in late 2013 after more than five years at the athletic apparel company, said the launch of the brand during the coronavirus pandemic comes at an "inflection point" for the retail industry. "I think some of the things the consumers are looking for are really that sustainability, versatility, longevity in their garments," said Day, also a former executive at Starbucks.

She said the House of LR&C is looking to fill a gap in the market with younger shoppers who are socially minded. "They want to see companies building business models that matter, that have inclusion and unity and sustainability and love, and there's not enough of that in this world," Day said.

The company's two clothing lines for now are Good Man Brand, which Wilson founded in 2016, and the newly launched Human Nation, which sells casual, gender-neutral items. A women's brand also is in the works, Day said.

The official launch of the House of LR&C this week comes during the holiday shopping season, which has been altered by the pandemic. Monday was the largest U.S. internet shopping day ever, according to Adobe Analytics data.

Clothes are for sale directly through its website, but Day said going beyond the direct-to-consumer route by inking partnerships with Kohl's and Nordstrom also is critical. Ciara said the House of LR&C's mission was aligned with the retailers that are known for their brick-and-mortar presence.

"If you look at the landscape and just how the world is changing, especially with ... companies like Kohl's, they're also evolving with the times," Ciara said. "I've been fortunate to do some really cool things with Kohl's already. We just like where they were going with things. We sat down and talked about our vision for what we were doing, we really connected, and we felt that the plan they had really made sense for what we were trying to do and vice versa."

Here is the original post:
Ciara and ex-Lululemon CEO launch new clothing brand with 'more to it than fashion' - CNBC

Select Page ::